"Interferon beta-1a" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An interferon beta-1 subtype that has a methionine at position 1, a cysteine at position 17, and is glycosylated at position 80. It functions as an ANTI-VIRAL AGENT and IMMUNOMODULATOR and is used to manage the symptoms of RELAPSING-REMITTING MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068556
|
| MeSH Number(s) |
D12.644.276.374.440.890.275.500 D12.776.467.374.440.890.275.500 D23.529.374.440.890.275.500
|
| Concept/Terms |
Interferon beta-1a- Interferon beta-1a
- beta-1a, Interferon
- Interferon beta 1a
- 1a, Interferon beta
- beta 1a, Interferon
Avonex- Avonex
- Avonex Pen
- Pen, Avonex
|
Below are MeSH descriptors whose meaning is more general than "Interferon beta-1a".
Below are MeSH descriptors whose meaning is more specific than "Interferon beta-1a".
This graph shows the total number of publications written about "Interferon beta-1a" by people in this website by year, and whether "Interferon beta-1a" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon beta-1a" by people in Profiles.
-
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020 Nov; 267(11):3343-3353.
-
Herpesvirus-Associated Lymphadenitis Distorts Fibroblastic Reticular Cell Microarchitecture and Attenuates CD8 T Cell Responses to Neurotropic Infection in Mice Lacking the STING-IFNa/ß Defense Pathways. J Immunol. 2016 09 15; 197(6):2338-52.
-
Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care. J Manag Care Pharm. 2013 Jan-Feb; 19(1 Suppl A):S1-53.
-
Serum IL-17F does not predict poor response to IM IFNß-1a in relapsing-remitting MS. Neurology. 2012 Aug 07; 79(6):531-7.
-
Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther. 2007 Jun; 29(6):1128-45.